Home > Haematology > EHA 2022 > Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD treatment

Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD treatment

Presented By
Dr Paul Bröckelmann, University Hospital of Cologne, Germany
Conference
EHA 2022
Trial
Phase 2, AERN
Treatment with nivolumab and radiotherapy at a single lesion is well tolerated and leads to an abscopal response in the majority of relapsed/refractory Hodgkin lymphoma patients who failed on anti-PD treatment, preliminary results of the AERN trial show. Anti-PD1 blockade has proven to be highly effective and is approved for the treatment of relapsed/refractory Hodgkin lymphoma. In addition, the progression-free survival (PFS) and overall survival (OS) outcomes are superior in patients achieving a complete response to anti-PD1 therapy [1]. However, most patients eventually develop progression of disease, constituting an unmet need due to a lack of approved novel treatment options. Local radiotherapy is postulated to induce systemic anti-tumour immunity leading to a tumour response outside the irradiated area. This so-called abscopal effect may be augmented by anti-PD1 therapy [2]. The ongoing AERN (Abscopal Effect of Radiotherapy and Nivolumab in R...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on